Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women
نویسندگان
چکیده
منابع مشابه
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
BACKGROUND Atazanavir/ritonavir (ATV/r) is a boosted protease inhibitor recommended to minimize the risk of mother-to-child HIV-1 transmission (MTCT). We aimed to assess the pharmacokinetics, safety and efficacy of ATV/r in HIV-1-infected pregnant women and their neonates. METHODS A multicentre, cross-sectional, non-interventional cohort of HIV-1-infected pregnant women receiving ATV/r (300/1...
متن کاملPopulation pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Methods Data were pooled from 3 DRV/RTV PK studies. In total 51 HIV-infected patients (7 female) stable on DRV/RTV (800/100mg or 900/100mg once daily; n=32 and 19, respectively) were included. Median age, weight, BMI, RTV area under the curve over 24h (AUC0-24) and baseline CD4 cell count were 39yr (21-63), 74kg (57-105), 24kg/m (18-31), 4.35mg.h/L (2.27-10.99) and 500cells/ mm (227-1129), resp...
متن کاملRitonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
BACKGROUND Although ritonavir-boosted atazanavir (ATV/r) is known to be associated with nephrolithiasis, little is known about the incidence of nephrolithiasis in patients treated with ritonavir-boosted Darunavir (DRV/r), the other preferred protease inhibitor. METHODS In a single-center cohort, the incidence of nephrolithiasis was compared between HIV-infected patients who commenced DRV/r-co...
متن کاملPopulation pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
OBJECTIVES The aim of this study was to develop and validate a population pharmacokinetic model to: (i) describe ritonavir-boosted atazanavir concentrations (300/100 mg once daily) and identify important covariates; and (ii) evaluate the predictive performance of the model for lower, unlicensed atazanavir doses (150 and 200 mg once daily) boosted with ritonavir (100 mg once daily). METHODS No...
متن کاملLopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
OBJECTIVES Lopinavir/ritonavir is approved for treatment of HIV-infected children at a dosage regimen of 230/57.5 mg/m(2) twice daily. However, once daily administration could increase convenience and patient adherence. Our study aimed at evaluating whether inhibitory concentrations are maintained in plasma following administration of lopinavir/ritonavir once daily. PATIENTS AND METHODS Lopin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: HIV Medicine
سال: 2011
ISSN: 1464-2662
DOI: 10.1111/j.1468-1293.2011.00927.x